SEARCH:   Advanced

Blood, 1 June 2006, Vol. 107, No. 11, pp. 4508-4513. Prepublished online as a Blood First Edition Paper on February 21, 2006; DOI 10.1182/blood-2005-08-3451. This Article Full Text (PDF) All Versions of this Article: 2005-08-3451v1 107/11/4508    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Loh, M. L Articles by Gilliland, D G Search for Related Content PubMed PubMed Citation Articles by Loh, M. L Articles by Gilliland, D G Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 26, 2005 Accepted January 20, 2006 Prospective analysis of TEL/AML1 positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01 Mignon L Loh*, Meredith A Goldwasser, Lewis B Silverman, Wing-Man Poon, Shashaank Vattikuti, Angelo Cardoso, Donna S Neuberg, Kevin M Shannon, Stephen E Sallan, and D G Gilliland Department of Pediatrics, University of California, San Francisco, CA, USA; Comprehensive Cancer Center, University of California, San Francisco, CA, USA Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium, Boston, MA, USA Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium, Boston, MA, USA; Children's Hospital, Boston, MA, USA Department of Pediatrics, University of California, San Francisco, CA, USA Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium, Boston, MA, USA Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA; Howard Hughes Institute of Medicine, Boston, MA, USA * Corresponding author; email: lohm{at}peds.ucsf.edu. In a retrospective analysis, we previously reported that children whose leukemia cells harbored the TEL/AML1 gene rearrangement have an excellent outcome. From 1996-2000, we conducted a prospective study to determine the incidence and outcome of children with TEL/AML1 positive ALL. Newly diagnosed children with ALL were treated on DFCI ALL Consortium Protocol 95-01. Patients were risk stratified primarily by current NCI-Rome risk criteria. With a median follow-up of 5.2 years, the five-year event-free survival for TEL/AML1-positive patients was 89% compared with 80% for TEL/AML1-negative B-precursor patients (p=0.05). Five-year overall survival was 97% among TEL/AML1-positive patients versus 89% among TEL/AML1-negative patients (p=0.03). However, in a multivariable analysis, risk group (age and leukocyte count at diagnosis) and asparaginase treatment group, but not TEL/AML1 status, were found to be independent predictors of outcome. We conclude that TEL/AML1-positive patients have an excellent outcome, confirming our previous findings. However, factors such as age at diagnosis and presenting leukocyte count should be taken into consideration when treating this group of patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Edwards, C. Xie, K. M. LaFiura, A. A. Dombkowski, S. A. Buck, J. L. Boerner, J. W. Taub, L. H. Matherly, and Y. Ge RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia Blood, September 24, 2009; 114(13): 2744 - 2752. [Abstract] [Full Text] [PDF] O. Teuffel, M. Stanulla, G. Cario, W. D. Ludwig, S. Rottgers, B. W. Schafer, M. Zimmermann, M. Schrappe, and F. K. Niggli Anemia and survival in childhood acute lymphoblastic leukemia Haematologica, November 1, 2008; 93(11): 1652 - 1657. [Abstract] [Full Text] [PDF] F. Tucci and M. Arico Treatment of pediatric acute lymphoblastic leukemia Haematologica, August 1, 2008; 93(8): 1124 - 1128. [Full Text] [PDF] J. E. Rubnitz, D. Wichlan, M. Devidas, J. Shuster, S. B. Linda, J. Kurtzberg, B. Bell, S. P. Hunger, A. Chauvenet, C.-H. Pui, et al. Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study J. Clin. Oncol., May 1, 2008; 26(13): 2186 - 2191. [Abstract] [Full Text] [PDF] J. Zhou, M. A Goldwasser, A. Li, S. E. Dahlberg, D. Neuberg, H. Wang, V. Dalton, K. D McBride, S. E. Sallan, L. B Silverman, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01 Blood, September 1, 2007; 110(5): 1607 - 1611. [Abstract] [Full Text] [PDF] E. Barry, D. J. DeAngelo, D. Neuberg, K. Stevenson, M. L. Loh, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, et al. Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols J. Clin. Oncol., March 1, 2007; 25(7): 813 - 819. [Abstract] [Full Text] [PDF] A. Moghrabi, D. E. Levy, B. Asselin, R. Barr, L. Clavell, C. Hurwitz, Y. Samson, M. Schorin, V. K. Dalton, S. E. Lipshultz, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia Blood, February 1, 2007; 109(3): 896 - 904. [Abstract] [Full Text] [PDF] N. J. Lacayo, J. F. DiMartino, M. C. Wei, and G. V. Dahl CpG Island Methylator Phenotype and Childhood Leukemia. Clin. Cancer Res., August 15, 2006; 12(16): 4787 - 4789. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020